The phase II ROSEWOOD study (NCT03332017) compared zanubrutinib plus obinutuzumab (ZO) with obinutuzumab monotherapy (O) in patients with relapsed/refractory (R/R) follicular lymphoma (FL) who had received two or more prior lines of systemic therapy. Median progression-free survival (PFS) was longer with ZO versus O [28.0 versus 10.4 months; hazard ratio 0.50, 95% confidence interval (CI) 0.33-0.75].
ESMO Open published a clinical update in Oncology on 31 Mar 2026.
The item focuses on Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from the ROSEWOOD study☆.
Review the original article for the full source wording and details.